Ribociclib

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1172 publications

Selective effects of cyclin dependent kinase inhibitors in gammaherpesvirus reactivation from latency.

Selective effects of cyclin dependent kinase inhibitors in gammaherpesvirus reactivation from latency.

Journal: bioRxiv : the preprint server for biology
Published: March 27, 2026

Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America.

Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America.

Journal: JCO global oncology
Published: March 19, 2026

Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis.

Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis.

Journal: Journal of pharmaceutical policy and practice
Published: February 23, 2026

Binding investigation of Ribociclib to human α-1-acid glycoprotein with spectroscopic and computational simulation approaches.

Binding investigation of Ribociclib to human α-1-acid glycoprotein with spectroscopic and computational simulation approaches.

Journal: Journal of biomolecular structure & dynamics
Published: February 19, 2026

Safe use of ribociclib in a patient with HR+/HER2- metastatic breast cancer receiving chronic hemodialysis.

Safe use of ribociclib in a patient with HR+/HER2- metastatic breast cancer receiving chronic hemodialysis.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: February 19, 2026

Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2- early breast cancer.

Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2- early breast cancer.

Journal: Wiener klinische Wochenschrift
Published: February 09, 2026

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

Journal: ESMO real world data and digital oncology
Published: February 06, 2026

Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

Journal: Journal of clinical medicine
Published: January 26, 2026

Design, Synthesis, and Preclinical Evaluation of Inhibitor-Based Radiotracers for Potential Application in Monitoring CDK4/6 Expression.

Design, Synthesis, and Preclinical Evaluation of Inhibitor-Based Radiotracers for Potential Application in Monitoring CDK4/6 Expression.

Journal: Journal of medicinal chemistry
Published: January 23, 2026

Correction: Vitiligo associated with ribociclib therapy: a rare case report.

Correction: Vitiligo associated with ribociclib therapy: a rare case report.

Journal: Frontiers in oncology
Published: January 18, 2026

Characteristics of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Eligible for Adjuvant Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors: Real-Life Evidence in a Colombian Cancer Center.

Characteristics of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Eligible for Adjuvant Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors: Real-Life Evidence in a Colombian Cancer Center.

Journal: Cureus
Published: January 18, 2026

Prognostic Value of Baseline Sarcopenia and Adipose Tissue Indices in HR+/HER2- Metastatic Breast Cancer Treated with CDK4/6 Inhibitors: A Retrospective Cohort Study.

Prognostic Value of Baseline Sarcopenia and Adipose Tissue Indices in HR+/HER2- Metastatic Breast Cancer Treated with CDK4/6 Inhibitors: A Retrospective Cohort Study.

Journal: Journal of clinical medicine
Published: January 11, 2026
Showing 1-12 of 1,172

Last Updated: 04/28/2026